US FDA Accelerated Approvals Could Expire Under New Legislation, But Big Loophole Included

The bill, some version of which is undoubtedly destined for the FDA user fee package, also would codify existing labeling guidance for products cleared through the pathway.

Rep. Frank Pallone, D-N.J. (Alamy image)
Rep. Frank Pallone's bill includes expedited accelerated withdrawal procedures for the FDA. • Source: Alamy

A new bill would add confirmatory trial deadlines to the US Food and Drug Administration’s accelerated approval pathway, but leaves a large opening that could allow sponsors to avoid them.

Rep. Frank Pallone, D-N.J., the chair of the House Energy and Commerce Committee, released the Accelerated Approval Integrity Act...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Review Pathways

More from Pathways & Standards